Insider Transactions in Q1 2021 at Tff Pharmaceuticals, Inc. (TFFP)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2021
|
Lung Therapeutics, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
715,000
-24.24%
|
$10,010,000
$14.0 P/Share
|
|
Mar 15
2021
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$85,000
$17.05 P/Share
|
|
Mar 15
2021
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$10,000
$2.5 P/Share
|
|
Mar 15
2021
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-83.33%
|
$850,000
$17.04 P/Share
|
|
Mar 15
2021
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+45.45%
|
$100,000
$2.5 P/Share
|
|
Mar 15
2021
|
Stephen Rocamboli Director |
SELL
Open market or private sale
|
Direct |
20,006
-56.0%
|
$320,096
$16.85 P/Share
|
|
Mar 15
2021
|
Stephen Rocamboli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,006
+22.72%
|
$60,018
$3.75 P/Share
|
|
Feb 16
2021
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$80,000
$16.82 P/Share
|
|
Feb 16
2021
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$10,000
$2.5 P/Share
|
|
Feb 16
2021
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
40,000
-80.0%
|
$640,000
$16.82 P/Share
|
|
Feb 16
2021
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+44.44%
|
$80,000
$2.5 P/Share
|
|
Feb 10
2021
|
Robert S Mills Director |
SELL
Open market or private sale
|
Direct |
700
-4.2%
|
$14,000
$20.16 P/Share
|
|
Feb 10
2021
|
Robert S Mills Director |
BUY
Exercise of conversion of derivative security
|
Direct |
700
+4.03%
|
$1,400
$2.5 P/Share
|
|
Jan 20
2021
|
Robert S Mills Director |
SELL
Open market or private sale
|
Direct |
12,600
-44.09%
|
$252,000
$20.2 P/Share
|
|
Jan 20
2021
|
Robert S Mills Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,600
+30.6%
|
$25,200
$2.5 P/Share
|
|
Jan 19
2021
|
Robert S Mills Director |
SELL
Open market or private sale
|
Direct |
55,100
-77.52%
|
$1,046,900
$19.56 P/Share
|
|
Jan 19
2021
|
Robert S Mills Director |
BUY
Exercise of conversion of derivative security
|
Direct |
55,100
+43.67%
|
$110,200
$2.5 P/Share
|
|
Jan 15
2021
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$85,000
$17.5 P/Share
|
|
Jan 15
2021
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$10,000
$2.5 P/Share
|
|
Jan 15
2021
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
40,000
-80.0%
|
$680,000
$17.51 P/Share
|
|
Jan 15
2021
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+44.44%
|
$80,000
$2.5 P/Share
|